Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780328 | 1.00 | LTA4H (0.45) | LTA4HPOLBHRH3CHRM3CHEK2 | |
| Hydrochloric Acid SCHEMBL1778603 | 0.78 | LTA4H (0.45) | LTA4HPOLBHRH3CHRM3 | |
| Hydrochloric Acid SCHEMBL1778284 | 0.76 | LTA4H (0.41) | LTA4HPOLBHRH3CHRM3 | |
| Hydrochloric Acid SCHEMBL1778287 | 0.76 | LTA4H (0.41) | LTA4HPOLBHRH3CHRM3 | |
| Hydrochloric Acid SCHEMBL1778782 | 0.74 | RAB9A (0.41) | LTA4HCHRM3HTR2A | |
| SCHEMBL23477699 | 0.73 | POLB (0.67) | LTA4HPOLBHRH3HTR2A | |
| SCHEMBL1777086 | 0.70 | LTA4H (0.45) | LTA4HPOLBHRH3CHRM3HTR2A | |
| SCHEMBL1777088 | 0.70 | LTA4H (0.45) | LTA4HPOLBHRH3CHRM3HTR2A | |
| SCHEMBL1776359 | 0.70 | LTA4H (0.45) | LTA4HPOLBHRH3 | |
| SCHEMBL1776357 | 0.70 | LTA4H (0.45) | LTA4HPOLBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943645-B2 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | LTA4H 930/4885POLB 4624/4885HRH3 23/4885 |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | LTA4H 990/4885POLB 4779/4885HRH3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.